Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SOPHiA GENETICS SA SOPH

Healthcare Medical Devices
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and... see more

Recent & Breaking News (NDAQ:SOPH)

SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting

PR Newswire June 15, 2022

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

PR Newswire June 15, 2022

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

PR Newswire June 9, 2022

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

PR Newswire June 6, 2022

SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting

PR Newswire June 1, 2022

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022  

GlobeNewswire May 10, 2022

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

PR Newswire May 5, 2022

SOPHiA GENETICS to Attend and Host Investor Meetings at the J.P. Morgan 50th Annual Global Technology, Media, and Communications Conference

GlobeNewswire April 27, 2022

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM(TM) Platform

PR Newswire April 26, 2022

SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2022 on May 10, 2022

GlobeNewswire April 13, 2022

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 15, 2022

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

PR Newswire March 14, 2022

SOPHiA GENETICS HRD Solution Adopted in Asia Pacific

PR Newswire March 9, 2022

SOPHiA GENETICS to Participate in Fireside Chat at Barclays Global Healthcare Conference

GlobeNewswire March 4, 2022

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

PR Newswire February 24, 2022

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

PR Newswire February 22, 2022

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

GlobeNewswire February 16, 2022

Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICS

PR Newswire February 1, 2022

SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer

PR Newswire January 26, 2022

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

PR Newswire January 11, 2022